4.8 Article

Structural basis for ligand reception by anaplastic lymphoma kinase

期刊

NATURE
卷 600, 期 7887, 页码 148-+

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41586-021-04141-7

关键词

-

资金

  1. NIH, NIGMS [R35 GM122485]
  2. NIH, NCI [R01 CA248532]
  3. National Institute of General Medical Sciences from the National Institutes of Health [P30 GM124165]
  4. NIH-ORIP HEI grant [S10 RR029205]
  5. DOE Office of Science [DE-AC02-06CH11357]
  6. National Cancer Institute [ACB-12002]
  7. National Institute of General Medical Sciences [AGM-12006]
  8. NIH [S10 OD012289]

向作者/读者索取更多资源

The proto-oncogene ALK encodes anaplastic lymphoma kinase, which is primarily expressed in the developing nervous system. Its activity is associated with learning and memory, energy expenditure, and obesity prevention. Aberrant ALK signaling causes various cancers, including being a driver in pediatric neuroblastoma. The study reveals the crystal structures of ALK's extracellular glycine-rich domain (GRD) and how it regulates receptor activity, providing insights into potential therapeutics for ALK-expressing cancers.
The proto-oncogene ALK encodes anaplastic lymphoma kinase, a receptor tyrosine kinase that is expressed primarily in the developing nervous system. After development, ALK activity is associated with learning and memory(1) and controls energy expenditure, and inhibition of ALK can prevent diet-induced obesity(2). Aberrant ALK signalling causes numerous cancers(3). In particular, full-length ALK is an important driver in paediatric neuroblastoma(4,5), in which it is either mutated(6) or activated by ligand(7). Here we report crystal structures of the extracellular glycine-rich domain (GRD) of ALK, which regulates receptor activity by binding to activating peptides(8,9). Fusing the ALK GRD to its ligand enabled us to capture a dimeric receptor complex that reveals how ALK responds to its regulatory ligands. We show that repetitive glycines in the GRD form rigid helices that separate the major ligand-binding site from a distal polyglycine extension loop (PXL) that mediates ALK dimerization. The PXL of one receptor acts as a sensor for the complex by interacting with a ligand-bound second receptor. ALK activation can be abolished through PXL mutation or with PXL-targeting antibodies. Together, these results explain how ALK uses its atypical architecture for its regulation, and suggest new therapeutic opportunities for ALK-expressing cancers such as paediatric neuroblastoma.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cell Biology

Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States

Heather Kalish, Carleen Klumpp-Thomas, Sally Hunsberger, Holly Ann Baus, Michael P. Fay, Nalyn Siripong, Jing Wang, Jennifer Hicks, Jennifer Mehalko, Jameson Travers, Matthew Drew, Kyle Pauly, Jacquelyn Spathies, Tran Ngo, Kenneth M. Adusei, Maria Karkanitsa, Jennifer A. Croker, Yan Li, Barry Graubard, Lindsay Czajkowski, Olivia Belliveau, Cheryl Chairez, Kelly R. Snead, Peter Frank, Anandakumar Shunmugavel, Alison Han, Luca T. Giurgea, Luz Angela Rosas, Rachel Bean, Rani Athota, Adriana Cervantes-Medina, Monica Gouzoulis, Brittany Heffelfinger, Shannon Valenti, Rocco Caldararo, Michelle M. Kolberg, Andrew Kelly, Reid Simon, Saifullah Shafiq, Vanessa Wall, Susan Reed, Eric W. Ford, Ravi Lokwani, John-Paul Denson, Simon Messing, Sam G. Michael, William Gillette, Robert P. Kimberly, Steven E. Reis, Matthew D. Hall, Dominic Esposito, Matthew J. Memoli, Kaitlyn Sadtler

Summary: The study analyzed undiagnosed SARS-CoV-2 infections in the United States and found a high prevalence rate, with different seropositivity estimates among various racial, age, gender, ethnic, and urban/rural groups. Data indicated that as of mid-July 2020, there were an estimated 16.8 million undiagnosed infections in the United States, with 4.8 undiagnosed cases for every diagnosed case of COVID-19.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Article Multidisciplinary Sciences

Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias

Chun Hu, Carlos A. Leche, Anatoly Kiyatkin, Zhaolong Yu, Steven E. Stayrook, Kathryn M. Ferguson, Mark A. Lemmon

Summary: The epidermal growth factor receptor (EGFR) frequently mutates in human cancer, and is an important therapeutic target. However, EGFR inhibitors have limited effectiveness in glioblastoma multiforme (GBM) due to exclusive mutations in the extracellular region. This study reveals that GBM mutations impair EGFR's ability to distinguish between activating ligands, which may have implications for therapeutic targeting.

NATURE (2022)

Article Chemistry, Medicinal

Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands

Maria-Elena Liosi, Joseph A. Ippolito, Sean P. Henry, Stefan G. Krimmer, Ana S. Newton, Kara J. Cutrona, Rene A. Olivarez, Jyotidarsini Mohanty, Joseph Schlessinger, William L. Jorgensen

Summary: This study aimed to develop binders that selectively target the JH2 domain of JAK2 and test their ability to modulate JAK2 activity in cells. Through computational design, synthesis, binding affinity measurements, permeability measurements, crystallography, and cell assays, the researchers successfully optimized a diaminotriazole compound that can inhibit the activity of JAK2 in cells.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Review Biochemistry & Molecular Biology

Looking lively: emerging principles of pseudokinase signaling

Joshua B. Sheetz, Mark A. Lemmon

Summary: Progress has been made in understanding the role of pseudokinases in biology and disease over the past decade. Despite lacking key catalytic residues, pseudokinases show striking similarity to their kinase relatives. Recent structural data suggest that both pseudokinases and bona fide kinases maintain distinct conformational states, which play a crucial role in their function. Understanding and targeting the conformational toggle in pseudokinases could have implications for disease treatment.

TRENDS IN BIOCHEMICAL SCIENCES (2022)

Article Chemistry, Medicinal

Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies

Sean P. Henry, Maria-Elena Liosi, Joseph A. Ippolito, Kara J. Cutrona, Stefan G. Krimmer, Ana S. Newton, Joseph Schlessinger, William L. Jorgensen

Summary: The study explored the potential of modulating JAK2 kinase activity by binding to the ATP site in JH2 domain and developed compounds with nanomolar affinity and high selectivity for JAK2 JH2 domain. Crystal structure analysis revealed the binding mechanism of these compounds with JAK2 JH2, offering a new platform for seeking molecules to regulate JAK2 signaling.

ACS MEDICINAL CHEMISTRY LETTERS (2022)

Article Multidisciplinary Sciences

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617

Lei Peng, Yingxia Hu, Madeleine C. Mankowski, Ping Ren, Rita E. Chen, Jin Wei, Min Zhao, Tongqing Li, Therese Tripler, Lupeng Ye, Ryan D. Chow, Zhenhao Fang, Chunxiang Wu, Matthew B. Dong, Matthew Cook, Guilin Wang, Paul Clark, Bryce Nelson, Daryl Klein, Richard Sutton, Michael S. Diamond, Craig B. Wilen, Yong Xiong, Sidi Chen

Summary: This study reports the development of monoclonal antibodies (mAbs) that effectively neutralize SARS-CoV-2 variants of concern. By using high-throughput single cell sequencing, the researchers identified two highly potent mAb clones with strong neutralizing activity against SARS-CoV-2 and its emerging variants. Cryo-EM structures revealed the distinct epitopes, binding patterns, and conformations of these neutralizing antibodies. The lead clones also showed potent efficacy in vivo against authentic SARS-CoV-2 in both preventive and therapeutic settings. Furthermore, a humanized antibody was generated and showed strong potency against both the original virus and the B.1.617.2 Delta variant. These mAbs expand the repertoire of therapeutics against SARS-CoV-2 and emerging variants.

NATURE COMMUNICATIONS (2022)

Article Multidisciplinary Sciences

De novo protein design of photochemical reaction centers

Nathan M. Ennist, Zhenyu Zhao, Steven E. Stayrook, Bohdana M. Discher, P. Leslie Dutton, Christopher C. Moser

Summary: Natural photosynthetic protein complexes are complex and fragile, making reengineering efforts challenging. In this study, researchers developed a simplified artificial photosynthetic reaction center protein that can efficiently convert solar energy into fuel. The protein showed high stability, modular structure, and nanometer-scale photochemical charge separation, making it ideal for light-activated catalysis. This study demonstrates the potential of synthetic biology in creating genetically encoded, light-powered catalysts for solar fuel production.

NATURE COMMUNICATIONS (2022)

Editorial Material Multidisciplinary Sciences

Unveiling molecular insights into the mechanism of activation of oncogenic phosphoinositide 3-kinase mutants

Stefan G. Krimmer, Joseph Schlessinger

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Multidisciplinary Sciences

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations

Iris K. van Alderwerelt van Rosenburgh, David M. Lu, Michael J. Grant, Steven E. Stayrook, Manali Phadke, Zenta Walther, Sarah B. Goldberg, Katerina Politi, Mark A. Lemmon, Kumar D. Ashtekar, Yuko Tsutsui

Summary: This study investigates the molecular basis for the varying response of non-small cell lung cancers driven by EGFR mutations to tyrosine kinase inhibitors. The researchers identify structural features that contribute to inhibitor sensitivity and propose a classification system for predicting clinical outcomes.

NATURE COMMUNICATIONS (2022)

Article Multidisciplinary Sciences

Cryo-EM analyses of KIT and oncogenic mutants reveal structural oncogenic plasticity and a target for therapeutic intervention

Stefan G. Krimmer, Nicole Bertoletti, Yoshihisa Suzuki, Luka Katic, Jyotidarsini Mohanty, Sheng Shu, Sangwon Lee, Irit Lax, Wei Mi, Joseph Schlessinger

Summary: The development of various cells, including hematopoietic stem cells and germ cells, relies on the receptor tyrosine kinase KIT and its ligand stem cell factor (SCF). Somatic mutations in KIT lead to several types of human cancers. Cryo electron microscopy analysis reveals that oncogenic KIT mutants exhibit distinct structural arrangements compared to wild-type KIT. The D5 region of KIT is identified as a potential target for therapeutic intervention.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Letter Urology & Nephrology

Variation in Best Practice Measures in Patients With Severe Hospital-Acquired Acute Kidney Injury: A Multicenter Study

Dennis G. Moledina, Olivia Belliveau, Yu Yamamoto, Tanima Arora, Kyle A. Carey, Matthew Churpek, Melissa Martin, Caitlin M. Partridge, Sherry G. Mansour, Chirag R. Parikh, Jay L. Koyner, F. Perry Wilson

AMERICAN JOURNAL OF KIDNEY DISEASES (2021)

暂无数据